Current treatment of chronic HBV infection: A North American perspective

Hui Hui Tan, Paul Martin

Research output: Contribution to journalArticle

Abstract

Chronic hepatitis B virus (HBV) infection remains a major cause of liver disease and hepatocellular carcinoma worldwide. Although less prevalent in the United States than in other areas of the world, HBV infection results in a significant disease burden in many American immigrant communities. Seven treatments are approved by the US Food and Drug Administration for the treatment of chronic HBV infection: interferon-α (standard interferon-α2b or pegylated interferon-α2a), and the nucleos(t)ide analogues lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. There is preliminary evidence that the disease burden from HBV infection may be diminishing in the United States, reflecting not only HBV vaccine progress but also more than a decade of antiviral therapy.

Original languageEnglish
Pages (from-to)148-153
Number of pages6
JournalCurrent Hepatitis Reports
Volume8
Issue number4
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Interferons
Tenofovir
Therapeutics
Hepatitis B Vaccines
Lamivudine
United States Food and Drug Administration
Antiviral Agents
Liver Diseases
Hepatocellular Carcinoma

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Current treatment of chronic HBV infection : A North American perspective. / Tan, Hui Hui; Martin, Paul.

In: Current Hepatitis Reports, Vol. 8, No. 4, 01.11.2009, p. 148-153.

Research output: Contribution to journalArticle

@article{5bdec8d8079c4c82ac436885b49ea8b5,
title = "Current treatment of chronic HBV infection: A North American perspective",
abstract = "Chronic hepatitis B virus (HBV) infection remains a major cause of liver disease and hepatocellular carcinoma worldwide. Although less prevalent in the United States than in other areas of the world, HBV infection results in a significant disease burden in many American immigrant communities. Seven treatments are approved by the US Food and Drug Administration for the treatment of chronic HBV infection: interferon-α (standard interferon-α2b or pegylated interferon-α2a), and the nucleos(t)ide analogues lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. There is preliminary evidence that the disease burden from HBV infection may be diminishing in the United States, reflecting not only HBV vaccine progress but also more than a decade of antiviral therapy.",
author = "Tan, {Hui Hui} and Paul Martin",
year = "2009",
month = "11",
day = "1",
doi = "10.1007/s11901-009-0021-y",
language = "English",
volume = "8",
pages = "148--153",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "4",

}

TY - JOUR

T1 - Current treatment of chronic HBV infection

T2 - A North American perspective

AU - Tan, Hui Hui

AU - Martin, Paul

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Chronic hepatitis B virus (HBV) infection remains a major cause of liver disease and hepatocellular carcinoma worldwide. Although less prevalent in the United States than in other areas of the world, HBV infection results in a significant disease burden in many American immigrant communities. Seven treatments are approved by the US Food and Drug Administration for the treatment of chronic HBV infection: interferon-α (standard interferon-α2b or pegylated interferon-α2a), and the nucleos(t)ide analogues lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. There is preliminary evidence that the disease burden from HBV infection may be diminishing in the United States, reflecting not only HBV vaccine progress but also more than a decade of antiviral therapy.

AB - Chronic hepatitis B virus (HBV) infection remains a major cause of liver disease and hepatocellular carcinoma worldwide. Although less prevalent in the United States than in other areas of the world, HBV infection results in a significant disease burden in many American immigrant communities. Seven treatments are approved by the US Food and Drug Administration for the treatment of chronic HBV infection: interferon-α (standard interferon-α2b or pegylated interferon-α2a), and the nucleos(t)ide analogues lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. There is preliminary evidence that the disease burden from HBV infection may be diminishing in the United States, reflecting not only HBV vaccine progress but also more than a decade of antiviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=70449482063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449482063&partnerID=8YFLogxK

U2 - 10.1007/s11901-009-0021-y

DO - 10.1007/s11901-009-0021-y

M3 - Article

AN - SCOPUS:70449482063

VL - 8

SP - 148

EP - 153

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 4

ER -